RAMSEY, N.J. and BOCA RATON, Fla. — August 6, 2025 — Leads & Copy — ADMA Biologics, Inc. (Nasdaq: ADMA) announced its second quarter 2025 financial results and provided a business update. The company reported a 14% year-over-year increase in total revenue, reaching $122.0 million. GAAP net income rose by 7% to $34.2 million. Adjusted EBITDA increased by 59% to $50.8 million, excluding a prior-year non-recurring item. Adjusted net income saw an 85% increase to $36.0 million, also excluding a prior-year item.
The company has initiated commercial-scale manufacturing with an FDA-approved yield enhancement process, with initial batches delivering over 20% increase in finished IG output. ADMA also secured a $300 million syndicated debt refinancing led by J.P. Morgan, which lowers borrowing costs and enhances strategic optionality.
Production operations infrastructure was expanded with the acquisition of a new Boca Raton operating site, strengthening the U.S. supply chain and potentially expanding cGMP manufacturing space by up to 30% at peak. The company reaffirmed its FY 2025–2026 total revenue, adjusted EBITDA, and adjusted net income guidance, projecting total annual revenue to reach $1.1 billion or more prior to 2030.
According to Florida Secretary of Commerce, J. Alex Kelly, Florida is leading the way in the life sciences sector.
Contact: Argot Partners | 212-600-1902 | ADMA@argotpartners.com
Source: ADMA Biologics, Inc.
